A serum MicroRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1207-1214

  Sahlberg, Kristine Kleivi ^a,b   Bottai, Giulia ^c   Naume, Bjørn ^a,d   Burwinkel, Barbara ^e,f   Calin, George A ^g   Børresen Dale, Anne Lise ^a,d   Santarpia, Libero ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Department of Research Vestre Viken ^*  (Norway)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 18B; MICRORNA 652; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENOME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MINIMALLY INVASIVE PROCEDURE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERUM; TRIPLE NEGATIVE BREAST CANCER; VALIDATION PROCESS; BLOOD; CANCER STAGING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TRANSCRIPTOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84928775471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2011     Document Type: Article

References (32)

1. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009;45:27-40.
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
3. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012;134:333-43.
4. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23:vi7-12.
5. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12: 847-65.
6. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, et al. The shaping and functional consequences of themicroRNA landscape in breast cancer. Nature 2013;497:378-82.
7. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39: 7223-33.
8. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012;18:5972-82.
9. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012;118: 2603-14.
10. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251:499-505.
11. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6.
12. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10: 472-84.
13. Ceppi P, Peter ME. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene 2014;33:269-78.
14. Chowdhury D, Choi YE, Brault ME. Charity begins at home: noncoding RNA functions in DNA repair. Nat Rev Mol Cell Biol 2013;14: 181-9.
15. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012;14:202.
16. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012;13:e178-85.
17. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. Cell 2010;141: 1195-207.
18. Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 2013;110:7413-7.
19. Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair 2013;12: 394-402.
20. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, et al. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS ONE 2013;8:e76729.
21. Wan YW, Mach CM, Allen GI, Anderson ML, Liu Z. On the reproducibility of TCGA ovarian cancer microRNA profiles. PLoS One 2014;9: e87782.
22. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47:784-91.
23. Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, et al. The rectal cancer microRNAome-microRNAexpression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012;18:4919-30.
24. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, et al. Distinct expressions of microRNAs that directly target estrogen receptor a in human breast cancer. Breast Cancer Res Treat 2011;130:331-9.
25. Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009;28: 3926-36.
26. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumours. PLoS ONE 2011;6:e16915.
27. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA.MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77.
28. Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, et al. microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 2014;14: 565-74.
29. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
30. Hallett RM, Dvorkin-Gheva A, Bane A, Hassell JA. A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep 2012;2:227.
31. Yau C, Sninsky J, Kwok S, Wang A, DegnimA, Ingle JN, et al. An optimized five-gene multi-platformpredictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res 2013;15:R103.
32. Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014;5:1174-84.